

Neurotech

Mente study to be presented at International Congress on Autism

Perth, Australia & Malta – 13 November 2018 – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) is pleased to announce it will be attending this year’s International Congress on Autism, organised by the World Autism Organisation, to be held in Houston, Texas on 12-15 November.

At the conference Prof. Frederick R. Carrick, from the Carrick Institute, will be presenting his research team’s study into Neurotech’s flagship Mente Autism device: *“The Treatment of Autism Spectrum Disorder With Auditory Neurofeedback: A Randomized Placebo Controlled Trial Using the Mente Autism Device”*.

Neurotech’s CEO Wolfgang Storf will also be in attendance to demonstrate the Mente Autism device.

Mr Storf said: “This is a leading conference on autism in the US and it is a great opportunity for us to meet medical professionals and demonstrate our flagship product. Dr Carrick’s presentation will, undoubtedly, provide a strong, scientific insight to participants on the successful outcomes of the clinical study.”

NEUROTECH AT MEDICA 2018

Neurotech will also be attending this year’s edition of Medica in Dusseldorf, Germany between 12 and 15 November, 2018. Medica is one of the largest trade fairs for the medical sector in the world. More than 5,000 exhibitors from 70 countries are attracted to the event. Neurotech has organised several meetings with prospective distribution partners during the event.

NEUROTECH AT ITALIAN CONFERENCE

Neurotech’s Chief Scientific Officer, Dr Emanuela Russo, will be giving a presentation at “Autism Spectrum Disorders: The body beyond the behaviour (A systemic perspective for an effective multidisciplinary approach)”, an autism conference being held in Caserta, Italy on 12-13 November 2018. Dr Russo will present on *“The Neurofeedback approach in supporting children on the autistic spectrum”*.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder. Designed for home use, it helps relax the minds of children on the spectrum which in turn helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420